Robot-assisted bronchoscopy for peripheral lung lesions: comparing Monarch and ION platforms
Official title: Robotic Systems Evaluation for Peripheral Pulmonary Lesions: A Randomized Trial (RISE Trial)
Run by Case Comprehensive Cancer Center · NCT07735611 · Data updated 2026-11-12
Doctors are testing two FDA-cleared robotic bronchoscopy tools to see which more often successfully sample peripheral lung lesions during a bronchoscopy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 398 (estimated) |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | October 2026 |
| Main results expected | August 2027 |
| Study ends | August 2027 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT07735611 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 and older scheduled for navigational bronchoscopy to evaluate a pulmonary lesion at UH Cleveland Medical Center.
✕Probably not a fit
Patients with enrollment in another bronchoscopic trial or those who do not undergo navigational bronchoscopy may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cluster-randomized trial comparing two FDA-cleared robotic bronchoscopy systems, the Monarch platform and the ION Endoluminal System, for sampling peripheral pulmonary lesions. Participants undergo planned robotic-assisted bronchoscopy using one of the two platforms. The study aims to determine which platform yields a higher diagnostic result in evaluating lung nodules, with procedures performed at UH Cleveland Medical Center. The trial builds on prior data suggesting substantial diagnostic yields for both systems when used with additional imaging techniques.
Why it matters
Potential benefit: If successful, the study could identify a preferred robotic approach that improves diagnostic yield for peripheral lung lesions.
How similar studies have gone: Previous studies and a recent RELIANT trial show high diagnostic yields for the ION system; Monarch has demonstrated effective sampling capabilities as well, making this comparison informative but not entirely novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years at the time of bronchoscopy. * Scheduled to undergo navigational bronchoscopy (either ION™ or Monarch™) for the evaluation of a pulmonary lesion at University Hospitals Cleveland Medical Center (UHCMC). * Able and willing to provide written informed consent. Exclusion Criteria: * Enrolled in another clinical trial that requires the use of a specific navigational/robotic bronchoscopy platform. * Enrolled in another bronchoscopy-related clinical trial. * Participant or legally authorized representative declines participation.
Where it's running
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Sameer K Avasarala, MD — Case Comprehensive Cancer Center, University Hospitals
- Study coordinator: Sameer K Avasarala, MD
- Email: Sameer.Avasarala@uhhospitals.org
- Phone: 216-844-3201
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating biomarkers for diagnosing and monitoring lung cancer
This study is testing if certain blood and tissue markers can help doctors better diagnose lung cancer and identify patients at risk for recurrence after surgery.
-
Collecting data to predict cancer risk in at-risk populations
This study is trying to collect samples and health information from people at higher risk of cancer to see if they can find signs that help predict cancer early on.
-
Safety and preliminary activity of BMS-986504 in unresectable MPNST
A new medicine called BMS-986504 is being tested to see if it is safe and may help people with unresectable malignant peripheral nerve sheath tumors, especially those whose tumors lack MTAP.
-
Wearable sensors and digital health in early cancer trials
This pilot study tests whether wearable activity tracking and electronic patient-reported outcomes can be feasibly used in early-phase cancer trials for adults.
-
HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer
This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.
-
MiraBurst to help with changes in taste from cancer treatment
This study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in adults with solid tumors who are undergoing cancer treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.